Navigation Links
Ludwig Institute of Cancer Research Ltd., Brussels Branch, Issues Statement Concerning Prospect Therapeutics Inc's. GCS-100 Molecule
Date:6/5/2009

WELLESLEY HILLS, Ma., June 5 /PRNewswire/ -- Joseph F. Finn, Jr., C.P.A. ("Finn") announced today that he has received a statement from Ludwig Institute of Cancer Research Ltd., Brussels Branch. The statement is quoted in its entirety below.

"Prospect Therapeutics' lead product candidate, GCS-100, is a carbohydrate molecule which inhibits the activity of Galectin-3, a protein found in high concentration in a broad range of human cancers. Prospect reported that GCS-100 could induce apoptosis of cancer cells and that clinical trial results indicated that reduction in leukemic cell number could be obtained without severe side effects.

"In addition to its direct effect on tumor cells, GCS-100 could have an important role on the immune system of cancer patients. A team at the Brussels Branch of the Ludwig Institute has found that human tumors contain a large number of T lymphocytes which are directed against specific antigens of the tumor cells, but that these lymphocytes are in a state of paralysis. An important component of this paralysis appears to be the trapping of T cell receptors in a galectin-3 lattice on the cell surface. The function of these T lymphocytes could readily be restored in vitro by addition of Galectin-binding sugar molecules, including GCS-100. This suggests that GCS-100 could be used in combination with anti-tumoral vaccination to induce the rejection of cancer cells in patients."

The intellectual property, regulatory dossier, fixed assets and clinical inventory of Prospect will be sold at auction on Monday, June 29, 2009 at 12:00 noon ET.

Persons interested in bidding must sign a Confidentiality Agreement ("CA") obtained from Finn's Office - jffinnjr@earthlink.net or 781-237-8840. They will then receive a bid package.

About Prospect Therapeutics, Inc.

Prospect's lead product candidate, GCS-100, is a carbohydrate molecule designed to inhibit the activity of galectin-3, a protein found in high concentration in a broad range of human cancers and whose over-expression is associated with poor prognosis in cancer patients.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the founding partner of the firm, Finn, Warnke & Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He works primarily in the area of management consulting for distressed enterprises, bankruptcy accounting and related matters, such as assignee for the benefit of creditors and liquidating agent for a corporation. He has been involved in a number of loan workouts and bankruptcy cases for thirty-five (35) years. His most recent Assignment for the Benefit of Creditors in the biotech field was Spherics, Inc. and ActivBiotics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at 781-237-8840 or jffinnjr@earthlink.net or visit the website at www.finnwarnkegayton.com


'/>"/>
SOURCE Joseph F. Finn, Jr., C.P.A.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Ludwig Institute for Cancer Research receives NHMRCs largest 2009 grant
2. The Risk Management and Patient Safety Institute Announces Annual Health Care Risk Conference Dates
3. Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute
4. LifeNet Health Establishes The Skin & Wound Allograft Institute
5. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
6. CAS Medical Systems, Inc. Awarded $2.8 Million Grant by National Institutes of Health
7. Portico Systems to Share Provider Network Management Best Practices at Institute for International Research
8. The Integrated Benefits Institute Offers Largest Benchmarking Database in U.S. Spanning Disability and Workers Compensation Programs
9. The Cooper Institutes FITNESSGRAM Selected as Statewide Physical Fitness Assessment Tool
10. Bullying Prevention Institute Designed to Empower Change in Schools
11. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... 27, 2016 , ... Quality metrics are proliferating in cancer care, and are ... the eye of the beholder, according to experts who offered insights and commentary in ... Managed Care. For the full issue, click here . , For the American ...
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... HILLS, Calif. , June 23, 2016 Any ... the many challenges of the current process. Many of them ... because of the technical difficulties and high laboratory costs involved. ... have to offer it at such a high cost that ... afford it. Dr. Parsa Zadeh , founder ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
Breaking Medicine Technology: